COMPANY UNVEILS NEW ARVIS® AUGMENTED REALITY SYSTEM, THE EMPOWR™ BLADE STEM AND MORE AT UPCOMING CONFERENCE IN TEXAS
Today, Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology company, announced it will showcase the latest technologies from its Surgical business, including an updated ARVIS® Augmented Reality System, EMPOWR™ blade stem, and EMPOWR 3D Knee® at the American Association of Hip and Knee Surgeons annual meeting in Grapevine, Texas, November 2-5, 2023.
“Enovis is dedicated to surgeon-centric innovation that creates value for all stakeholders and ultimately improves patient outcomes,” stated Louie Vogt, President and General Manager of Enovis™ Surgical. “Cost effective and scalable enabling technologies have a bright future and we’re excited to take our ARVIS Augmented Reality System to the next level with new features that enable surgeons to quickly plan, execute and verify precise implant alignment, as well as now offering implant rotation and tissue balancing capabilities. We’re also thrilled to be launching our EMPOWR blade stem, which is designed to fit better than traditional blade stems and offers intraoperative efficiency through expanded options and streamlined instrumentation.”
Other offerings being showcased will include EMPOWR 3D Knee® which is the first and only dual pivot total knee on the market replicating natural motion.2,3 Additionally, Enovis will be hosting a symposium discussing our efficient revision offerings, EMPOWR Revision Knee and EXPRT Hip System.
AAHKS attendees can experience these products firsthand at booth #501.
References:
- Competitive data retrieved from competitors’ websites
- Meneghini, R. M., Deckard, E. R., Ishmael, M. K., & Ziemba-Davis, M. (2017). A dual-pivot pattern simulating native knee kinematics optimizes functional outcomes after total knee arthroplasty. The Journal of Arthroplasty, 32(10), 3009–3015. https://doi.org/10.1016/j.arth.2017.04.050
- Sandberg, Rory, et al. “Dual-pivot bearings improve ambulation and promote increased activity levels in Total knee arthroplasty: A match-controlled retrospective study.” The Knee 26.6 (2019): 1243-1249.
ABOUT ENOVIS
Enovis Corporation (NYSE: ENOV) is an innovation-driven medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. Powered by a culture of continuous improvement, global talent and innovation, the Company’s extensive range of products, services and integrated technologies fuels active lifestyles in orthopedics and beyond. The Company’s shares of common stock are listed in the United States on the New York Stock Exchange under the symbol ENOV. For more information about Enovis, please visit www.enovis.com.
Media Contact
Kristen Vick
Enovis Surgical
Kristen.Vick@enovis.com